newsfilter
← Latest News
Earnings Call Transcripts·

10X GENOMICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - 10X GENOMICS INC

  • Explicit Guidance:

    • FY2026 Instrument Sales: Confirmed target to sell 50 Terra instruments in FY2026 (reiterated from prior guidance); management expressed confidence in scaling to building and shipping 50 units per quarter by Q1.
    • Consumable Growth Trajectory: Expects single-cell consumables to remain in a "dynamic transition" with headwinds from Apex volume growth offsetting pricing pressure; anticipates a measure of equilibrium where incremental Apex growth contributes to the top line within "another couple of quarters," aiming for double-digit consumable growth once this transition stabilizes.
    • Xenium Growth: Anticipates sequential growth slowdown in Xenium Q4 and into the near term as Terra adoption accelerates, though not expecting an immediate "fall off a cliff."
    • Cash Generation: Reported generation of close to $100 million in cash over the last 12 months, strengthening balance sheet for potential strategic moves (though not a specific forward guidance figure, it informs future capex/M&A capacity).
  • Business-Segment Outlook:

    • Terra (New Platform): Described as having "blown the doors off" the market with interest exceeding high initial expectations; significant traction from non-Xenium owners (including new spatial users) and large institutions/consortia.
    • Xenium (Legacy Spatial): Expected to continue growing robustly but will face pressure from Terra cannibalization; will continue to be a "rapidly growing platform" in its own right.
    • Single-Cell (Chromium/Flex/Apex): Double-digit reaction growth persists in Flex/Apex; strategy involves driving volume via lower-cost Apex to offset pricing headwinds, with total consumables volume growing "in excess of expectations."
    • Catalyst Research Services (CRS): Seeing "dramatic" demand with over 100 customers; expanding capacity by allocating more instruments to services; view is a secular shift toward services/insights for grant advocacy and instrument validation.
    • Clinical & Diagnostics: Building a CLIA lab to launch Laboratory Developed Tests (LDTs) and running clinical cohorts with medical centers globally to generate evidence linking spatial biomarkers to clinical outcomes, particularly in oncology.
  • Market and Competitive Outlook:

    • Market Leadership: Management believes the company is "multiple generations ahead" of competitors; sees Terra as the natural technology for future large-scale perturbation screens and foundation model training, surpassing dissociated single-cell methods at scale.
    • Competitive Landscape: Views consolidation (e.g., Nanostring, Fluidigm exits) as non-threatening to their moat; intends to win via continuous R&D and product superiority rather than M&A.
    • Demand Trends: Anticipates massive scale expansion in AI-driven biology (moving from millions to "hundreds of billions" of cells); sees strong pull from biopharma, diagnostics companies with clinical samples, and AI-native companies.
    • Clinical Pathway: Identifies a "huge unmet need" for comprehensive multi-target profiling to guide new therapeutic modalities (ADCs, bispecifics, T-cell engagers) beyond current IHC capabilities; predicts spatial/single-cell will become the standard for clinical decision support as workflow standardization improves.
  • Macro / Industry Outlook:

    • AI Convergence: Views AI as a structural tailwind; Terra is "perfectly built" for the new era of AI, with spatial data expected to become the primary foundation for future biology foundation models.
    • Funding Environment: Notes academic and government funding remains pressured, but overall macro trends are "in our favor" driven by private sector (biopharma, biotech) spending and AI enthusiasm.
    • Workflow Integration: Anticipates the convergence of genomics and pathology will accelerate due to AI's ability to process data and Terra's compatibility with standard H&E slides, simplifying pathologist adoption.
  • Strategic Initiatives:

    • Automation: Developing instrument automation to make Terra workflow "the simplest... in genomics" (slide-in, data-out); currently optimizing field service engineer capacity and site readiness.
    • CLIA Lab Establishment: Launching an internal CLIA lab to validate concepts and enable LDTs, serving as a proof-of-concept for clinical diagnostics.
    • M&A Strategy: No immediate priority on M&A; focus remains on operational efficiency and organic growth. Will consider acquisitions only if they have a "really good strategic rationale" and fit the current strategy, backed by a strong balance sheet.
    • Capacity Expansion: Scaling instrument production to 50 units per quarter by Q1 FY2026; currently constrained by the need to balance instrument deployment for customer success (field service) vs. internal CRS projects.
  • Risks and Headwinds to Outlook:

    • Supply and Deployment: Near-term revenue growth is constrained by the ability to produce, ship, and install Terra instruments; "field service engineer capacity" and site readiness issues are key rate-limiting factors.
    • Cannibalization: Potential sequential decline in Xenium consumables as customers migrate to Terra; monitoring "pull-through" rates at dual-platform customers.
    • Pricing Dynamics: Continued volume-driven price erosion from Apex strategy may suppress top-line growth for "another couple of quarters" before equilibrium is reached.
    • Implementation Friction: Early installations face "little tweaks" (site readiness, shipping, configuration) requiring field support to ensure customer success and consumable conversion.
  • Management Tone on the Future:

    • Confidence Level: High; described Terra launch as "really, really fun" with enthusiasm "exceeding expectations"; expressed "real confidence" in the 50-unit quarterly build target by Q1.
    • Strategic Clarity: Management views the current transition (Apex pricing, Terra ramp) as dynamic but expected, with "measure of equilibrium" anticipated soon; sees a clear, long-term structural shift toward spatial AI and clinical diagnostics.
    • Optimism: Strong conviction that they are uniquely positioned to "accelerate the arrival" of the clinical future, with a "huge potential" in oncology diagnostics.
    • Caveats: Repeated emphasis that Terra is "very early days" with a small N (number of customers), limiting near-term granularity on long-term unit economics.
  • Miscellaneous:

    • Customer Diversification: Early Terra adoption includes diverse cohorts: existing Xenium owners, new spatial buyers, biotech, AI-native companies, and non-traditional sectors (e.g., Procter & Gamble).
    • Competitor Exits: Management explicitly noted the exits of Nanostring and Fluidigm as context for the current landscape but dismissed them as immediate threats to their technological moat.
Company
10X GENOMICS INC
Keywords
10X GENOMICS INC